Domain Therapeutics Launches Phase 1 Trials on Patented EP4...

Domain Therapeutics Launches Phase 1 Trials on Patented EP4 Receptor Antagonist

Healthcare Tech Outlook | Thursday, December 24, 2020

Domain Therapeutics has developed a patented small molecule-based software designed to treat ICI-mediated Prostaglandin E2-immunosuppression.

FREMONT, CA: Domain Therapeutics, a biopharmaceutical company, specializing in discovering and producing new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, neurology, and rare diseases, has announced the start of Phase 1 trials with DT-9081, its patented EP4 receptor antagonist candidate for cancer treatment. GPCRs belong to the membrane receptor family and are critical groups of therapeutic targets for many indications.

The study of immunosuppressive mechanisms responsible for the minimal efficacy of Immunosuppressive Inhibitors (ICIs) in the clinic led to the discovery and inception of the EP4 GPCR receptor (EP4R). Some tumors release Prostaglandin E2, the natural EP4R ligand expressed by some immune cells, contributing to the tumor’s immune escape. This protumoral microenvironment can lead to altering the behavior of some ICIs. Thus, the combination of an EP4R antagonist with ICI can restore their therapeutic effect and further expand patients’ population responding to ICI therapies.

Domain Therapeutics has developed a patented small molecule-based software designed to treat ICI-mediated Prostaglandin E2-immunosuppression. The company chose a production candidate and initiated the Chemistry, Manufacturing, and Control (CMC) operations. The business is currently transforming preclinical biomarkers into clinical biomarkers to add value to clinical growth.Domain, which functions in France and Canada, has developed a proprietary pipeline of high-value drug candidates for immuno-oncology, neurology, and rare diseases. The organization has entered into several partnering arrangements with pharmaceutical companies.

“This step constitutes a significant company milestone; DT-9081 is the second immuno-oncology program to reach Phase 1-enabling studies - after the Adenosine Receptor antagonist drug candidate developed in partnership with Merck KGaA,” said Pascal Neuville, CEO, Domain Therapeutics. “Developing our proprietary drug candidates towards the clinical phase will significantly increase the value of Domains portfolio.”

Weekly Brief